<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="Daridorexant" content-type="chapter" from-where="body" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">livertox</book-id>
    <book-title-group>
      <book-title>LiverTox</book-title>
      <subtitle>Clinical and Research Information on Drug-Induced Liver Injury</subtitle>
    </book-title-group>
    <pub-date date-type="pubr" publication-format="electronic">
      <year>2012</year>
    </pub-date>
    <publisher>
      <publisher-name>National Institute of Diabetes and Digestive and Kidney Diseases</publisher-name>
      <publisher-loc>Bethesda (MD)</publisher-loc>
    </publisher>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <book-part-id book-part-id-type="pmcid">Daridorexant</book-part-id>
      <title-group>
        <title>Daridorexant</title>
      </title-group>
      <pub-history>
        <date date-type="updated">
          <day>5</day>
          <month>2</month>
          <year>2025</year>
        </date>
      </pub-history>
      <related-object link-type="parent-book-link" source-id="livertox">LiverTox: Clinical and Research Information on Drug-Induced Liver Injury</related-object>
      <related-object link-type="previous-part-link" source-id="livertox" document-id="Daratumumab" document-type="chapter">Daratumumab</related-object>
      <related-object link-type="next-part-link" source-id="livertox" document-id="Darifenacin" document-type="chapter">Darifenacin</related-object>
    </book-part-meta>
    <body>
      <sec id="Daridorexant.OVERVIEW">
        <title>OVERVIEW</title>
        <sec id="Daridorexant.Introduction" sec-type="pubmed-excerpt">
          <title>Introduction</title>
          <p>Daridorexant is an orexin receptor antagonist currently used in the treatment of insomnia in adults. Daridorexant is associated with rare instances of elevations in serum aminotransferase levels during therapy but has not been implicated in cases of clinically apparent liver injury.</p>
        </sec>
        <sec id="Daridorexant.Background">
          <title>Background</title>
          <p>Daridorexant (da ree&#x0201d; doe rex&#x02019; ant) is an orexin receptor antagonist used for therapy of insomnia in adults. Orexin is a neuropeptide that plays a role in wakefulness and central nervous system neurons, with orexin receptors that are activated during wakeful periods and are inactive during sleep. Engagement of the orexin receptor results in wakefulness, and loss of the receptor can result in excessive daytime sleepiness and narcolepsy. Antagonism of orexin receptors causes somnolence and promotes sleep. In several randomized controlled trials, daridorexant shortened the latency to onset of sleep and helped maintain sleep, prolonging the time to wake after sleep onset. Daridorexant was approved for use in the United States in 2022, the third orexin receptor antagonist made available (suvorexant 2014 and lemborexant 2019). Daridorexant is available under the brand name Quviviq in tablets of 25 and 50 mg, the recommended dose in adults being 25 mg taken within 30 minutes of bedtime. The dose can be raised to 50 mg but higher doses should not be used. Side effects are usually mild but can include headache, somnolence, and fatigue. Daridorexant taken before bedtime can also cause some degree of daytime somnolence, impairment of driving or using heavy machinery. Uncommon (occurring in less than 1% of persons) but potentially troublesome adverse events include sleep paralysis and complex sleep behaviors (such as sleepwalking and hallucinations). Daridorexant can also worsen depression and decrease respiratory function and should be used with caution in persons on antidepressants or with respiratory dysfunction. Daridorexant is classified as a Schedule 4 controlled substance, meaning that it has a low potential for abuse or dependence and has an approved medical use.</p>
        </sec>
        <sec id="Daridorexant.Hepatotoxicity">
          <title>Hepatotoxicity</title>
          <p>In two controlled trials conducted in support of approval of daridorexant in the United States, there were no changes in serum ALT, AST, alkaline phosphatase or bilirubin levels during treatment and no instances of drug induced liver injury. Since its approval and more widespread clinical use, there have been no published reports of clinically apparent liver injury attributed to daridorexant. Indeed, the two previously approved orexin receptor antagonists available in the United States were also found to be free of hepatic adverse effects.</p>
          <p>Likelihood score: E (unlikely cause of clinically apparent liver injury).</p>
        </sec>
        <sec id="Daridorexant.Mechanism_of_Injury">
          <title>Mechanism of Injury</title>
          <p>The mechanism by which daridorexant might cause serum aminotransferase elevations is not known. It is metabolized in the liver by the P450 system, largely by CYP 3A4 and is susceptible to drug-drug interactions. The dose of daridorexant may have to be adjusted if there is concurrent therapy with moderate or strong CYP 3A4 inhibitors (which can increase daridorexant levels) or inducers (which could lower levels of daridorexant).</p>
        </sec>
        <sec id="Daridorexant.Outcome_and_Management">
          <title>Outcome and Management</title>
          <p>There is no evidence that daridorexant can cause liver injury, and development of ALT or AST elevations or clinical evidence of liver injury during therapy should lead to search for another cause.</p>
          <p>Drug Class: <related-object link-type="booklink" source-id="livertox" document-id="Sedatives_Hypnotics" document-type="book-part">Sedatives and Hypnotics</related-object>; Drugs for Insomnia</p>
          <p>Other Orexin Receptor Antagonists: <related-object link-type="booklink" source-id="livertox" document-id="Lemborexant" document-type="book-part">Lemborexant</related-object>, <related-object link-type="booklink" source-id="livertox" document-id="Suvorexant" document-type="book-part">Suvorexant</related-object></p>
        </sec>
      </sec>
      <sec id="Daridorexant.PRODUCT_INFORMATION">
        <title>PRODUCT INFORMATION</title>
        <p>
<bold>REPRESENTATIVE TRADE NAMES</bold>
</p>
        <p>Daridorexant &#x02013; Quviviq&#x000ae;</p>
        <p>
<bold>DRUG CLASS</bold>
</p>
        <p>Sedatives and Hypnotics</p>
        <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&#x00026;query=Daridorexant">COMPLETE LABELING</ext-link>
</p>
        <p>Product labeling at DailyMed, National Library of Medicine, NIH</p>
      </sec>
      <sec id="Daridorexant.CHEMICAL_FORMULA_AND_STRUCT">
        <title>CHEMICAL FORMULA AND STRUCTURE</title>
        <table-wrap id="Daridorexant.Tc" orientation="portrait" position="anchor">
          <table frame="hsides" rules="groups">
            <thead>
              <tr>
                <th id="hd_h_Daridorexant.Tc_1_1_1_1" valign="top" align="left" scope="col" rowspan="1" colspan="1">DRUG</th>
                <th id="hd_h_Daridorexant.Tc_1_1_1_2" valign="top" align="left" scope="col" rowspan="1" colspan="1">CAS REGISTRY NUMBER</th>
                <th id="hd_h_Daridorexant.Tc_1_1_1_3" valign="top" align="left" scope="col" rowspan="1" colspan="1">MOLECULAR FORMULA</th>
                <th id="hd_h_Daridorexant.Tc_1_1_1_4" valign="top" align="left" scope="col" rowspan="1" colspan="1">STRUCTURE</th>
              </tr>
            </thead>
            <tbody>
              <tr>
                <td headers="hd_h_Daridorexant.Tc_1_1_1_1" valign="top" align="left" scope="row" rowspan="1" colspan="1">Daridorexant</td>
                <td headers="hd_h_Daridorexant.Tc_1_1_1_2" valign="top" align="left" rowspan="1" colspan="1">
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pubchem" xlink:href="sid://348351285">1505484-82-1</ext-link>
</td>
                <td headers="hd_h_Daridorexant.Tc_1_1_1_3" valign="top" align="left" rowspan="1" colspan="1">C23-H23-ClN6-O2</td>
                <td headers="hd_h_Daridorexant.Tc_1_1_1_4" valign="top" align="left" rowspan="1" colspan="1">
<related-object link-type="ext-image-back-link" source-id="pubchem" document-id="348351285" document-id-type="sid" document-type="summary" object-id="348351285" object-id-type="sid" object-type="image"/>
</td>
              </tr>
            </tbody>
          </table>
        </table-wrap>
      </sec>
      <sec id="Daridorexant.ANNOTATED_BIBLIOGRAPHY">
        <title>ANNOTATED BIBLIOGRAPHY</title>
        <p>References updated: 05 February 2025</p>
        <ref-list id="Daridorexant.ANNOTATED_BIBLIOGRAPHY.reflist0">
          <ref id="Daridorexant.REF.zimmerman.1999">
            <mixed-citation publication-type="book">Zimmerman HJ. Hepatotoxicity: the adverse effects of drugs and other chemicals on the liver. 2nd ed. Philadelphia: Lippincott, 1999.<annotation><p><italic toggle="yes">(Expert review of hepatotoxicity published in 1999 before the availability of orexin receptor antagonists).</italic></p></annotation></mixed-citation>
          </ref>
          <ref id="Daridorexant.REF.larrey.2013">
            <mixed-citation publication-type="book">Larrey D, Ripault MP. Anxiolytic agents. Hepatotoxicity of psychotropic drugs and drugs of abuse. In, Kaplowitz N, DeLeve LD, eds. Drug-induced liver disease. 3rd ed. Amsterdam: Elsevier, 2013, p. 455-6.<annotation><p><italic toggle="yes">(Review of hepatotoxicity of hypnotics and sedatives discusses benzodiazepines, buspirone and valerian, all of which have been linked to rare cases of liver injury; daridorexant and other orexin receptor antagonists are not discussed).</italic></p></annotation></mixed-citation>
          </ref>
          <ref id="Daridorexant.REF.mihic.2018">
            <mixed-citation publication-type="book">Mihic SJ, Mayfield J, Harris RA. Hypnotics and sedatives. In, Brunton LL, Hilal-Dandan R, Knollman BC, eds. Goodman &#x00026; Gilman's the pharmacological basis of therapeutics. 13th ed. New York: McGraw-Hill, 2018, pp. 339-353.<annotation><p><italic toggle="yes">(Textbook of pharmacology and therapeutics, discusses suvorexant but not daridorexant).</italic></p></annotation></mixed-citation>
          </ref>
          <ref id="Daridorexant.REF4">
            <mixed-citation publication-type="web">FDA. Integrated Review. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/214985Orig1s000IntegratedR.pdf">https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/214985Orig1s000IntegratedR.pdf</ext-link><annotation><p><italic toggle="yes">(FDA website with product labels and FDA review of the data on efficacy and safety submitted by the sponsor in support of the approval of daridorexant mentions side effects of somnolence, headache, and fatigue; no mention of ALT elevations or hepatotoxicity, but there was &#x0201c;no indication of any potential effect of daridorexant on laboratory values&#x0201d; including liver function tests).</italic></p></annotation></mixed-citation>
          </ref>
          <ref id="Daridorexant.REF.chalasani.2015.1340">
            <mixed-citation publication-type="journal"><string-name name-style="western"><surname>Chalasani</surname>
<given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Bonkovsky</surname>
<given-names>HL</given-names></string-name>, <string-name name-style="western"><surname>Fontana</surname>
<given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Lee</surname>
<given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Stolz</surname>
<given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Talwalkar</surname>
<given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Reddy</surname>
<given-names>KR</given-names></string-name>, <etal>et al.</etal>; <collab>United States Drug Induced Liver Injury Network</collab>. <article-title>Features and outcomes of 899 patients with drug-induced liver injury: the DILIN Prospective Study.</article-title>
<source>Gastroenterology</source>
<year>2015</year>; <volume>148</volume>: <fpage seq="a">1340</fpage>-<lpage>52.e7</lpage>.<annotation><p><italic toggle="yes">(Among 899 cases of drug induced liver injury enrolled in a US prospective study between 2004 and 2013, no cases were attributed to drugs for insomnia).</italic></p></annotation><pub-id pub-id-type="pmid">25754159</pub-id>
</mixed-citation>
          </ref>
          <ref id="Daridorexant.REF.muehlan.2018.1022">
            <mixed-citation publication-type="journal"><string-name name-style="western"><surname>Muehlan</surname>
<given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Heuberger</surname>
<given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Juif</surname>
<given-names>PE</given-names></string-name>, <string-name name-style="western"><surname>Croft</surname>
<given-names>M</given-names></string-name>, <string-name name-style="western"><surname>van Gerven</surname>
<given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Dingemanse</surname>
<given-names>J</given-names></string-name>. <article-title>Accelerated development of the dual orexin receptor antagonist ACT-541468: integration of a microtracer in a first-in-human study.</article-title>
<source>Clin Pharmacol Ther.</source>
<year>2018</year>;<volume>104</volume>:<fpage>1022</fpage>-<lpage>1029</lpage>.<annotation><p><italic toggle="yes">(Analysis of the absorption, bioavailability, pharmacokinetics, metabolism, and tolerance of daridorexant in 40 healthy volunteers, in whom side effects were mild-to-moderate only and included somnolence, fatigue, disturbance in concentration, and headache).</italic></p></annotation><pub-id pub-id-type="pmid">29446069</pub-id>
</mixed-citation>
          </ref>
          <ref id="Daridorexant.REF.mignot.2022.125">
            <mixed-citation publication-type="journal"><string-name name-style="western"><surname>Mignot</surname>
<given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Mayleben</surname>
<given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Fietze</surname>
<given-names>I</given-names></string-name>, <string-name name-style="western"><surname>Leger</surname>
<given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Zammit</surname>
<given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Bassetti</surname>
<given-names>CLA</given-names></string-name>, <string-name name-style="western"><surname>Pain</surname>
<given-names>S</given-names></string-name>, <etal>et al.</etal>; <article-title>investigators. Safety and efficacy of daridorexant in patients with insomnia disorder: results from two multicentre, randomised, double-blind, placebo-controlled, phase 3 trials.</article-title>
<source>Lancet Neurol.</source>
<year>2022</year>;<volume>21</volume>:<fpage>125</fpage>-<lpage>139</lpage>.<annotation><p><italic toggle="yes">(Among 1854 adults with insomnia treated with daridorexant [10, 25, or 50 mg] or placebo once before bedtime for 3 months, latency to sleep onset and maintenance of sleep increased with the higher doses by an average of 10-20 minutes compared to placebo, while side effects included headache [4%-6% vs 4%), fatigue [2%-4% vs 1%] somnolence [2%-4% vs 2%]; no mention of ALT elevations or hepatotoxicity).</italic></p></annotation><pub-id pub-id-type="pmid">35065036</pub-id>
</mixed-citation>
          </ref>
          <ref id="Daridorexant.REF8">
            <mixed-citation publication-type="journal"><article-title>Daridorexant (Quviviq) for insomnia.</article-title>
<source>Med Lett Drugs Ther.</source>
<year>2022</year>;<volume>64</volume>:<fpage>107</fpage>-<lpage>110</lpage>.<annotation><p><italic toggle="yes">(Concise summary of the mechanism of action, clinical efficacy, safety, and costs of daridorexant shortly after its approval as therapy for insomnia in the US mentions adverse events of headache, somnolence, and fatigue [5%-7%] and more rarely daytime sleepiness, sleep paralysis, and hallucinations [&#x0003c;1%]; no mention of ALT elevations or hepatotoxicity).</italic></p></annotation><pub-id pub-id-type="pmid">35802843</pub-id>
</mixed-citation>
          </ref>
          <ref id="Daridorexant.REF.kunz.2023.93">
            <mixed-citation publication-type="journal"><string-name name-style="western"><surname>Kunz</surname>
<given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Dauvilliers</surname>
<given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Benes</surname>
<given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Garc&#x000ed;a-Borreguero</surname>
<given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Plazzi</surname>
<given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Seboek Kinter</surname>
<given-names>D</given-names></string-name>, <etal>et al.</etal>
<article-title>Long-term safety and tolerability of daridorexant in patients with insomnia disorder.</article-title>
<source>CNS Drugs.</source>
<year>2023</year>;<volume>37</volume>:<fpage>93</fpage>-<lpage>106</lpage>.<annotation><p><italic toggle="yes">(Among 801 adults with insomnia who participated in a 12-week controlled trial of daridorexant who were enrolled in a 40-week extension trial, improvements in sleep were sustained and adverse events remained mild and infrequent including falls, headache and somnolence in &#x0003c;3%, and dizziness and fatigue &#x0003c;2%, and there were &#x0201c;no clinically significant findings for any changes in hematology or chemistry parameters&#x0201d;).</italic></p></annotation><pub-id pub-id-type="pmid">36484969</pub-id>
</mixed-citation>
          </ref>
          <ref id="Daridorexant.REF10">
            <mixed-citation publication-type="journal"><article-title>Drugs for chronic insomnia.</article-title>
<source>Med Lett Drugs Ther.</source>
<year>2023</year>;<volume>65</volume>:<fpage>1</fpage>-<lpage>6</lpage>.<annotation><p><italic toggle="yes">(Concise description of drugs approved for use in chronic insomnia including relative efficacy, safety and costs, mentions that daridorexant like other orexin receptor inhibitors improves latency to falling asleep by 5-10 minutes and duration of sleep to waking by 15 to 25 minutes compared to placebo, and that the most common adverse events are somnolence, fatigue, headache, and abnormal dreams).</italic></p></annotation><pub-id pub-id-type="pmid">36630579</pub-id>
</mixed-citation>
          </ref>
          <ref id="Daridorexant.REF.preskorn.2023.38">
            <mixed-citation publication-type="journal"><string-name name-style="western"><surname>Preskorn</surname>
<given-names>SH</given-names></string-name>. <article-title>Comparative pharmacology of the 3 marketed dual orexin antagonists-daridorexant, lemborexant, and suvorexant-part 2. principal drug metabolizing enzyme, drug-drug interactions, and effects of liver and renal impairment on metabolism.</article-title>
<source>J Psychiatr Pract.</source>
<year>2023</year>;<volume>29</volume>:<fpage>38</fpage>-<lpage>41</lpage>.<annotation><p><italic toggle="yes">(Review of the pharmacokinetics of the 3 orexin antagonists in clinical use, including suvo-, lembo-, and darido-rexant, mentions that they have similar chemical structures and similar metabolism by CYP 3A4, with only minor differences in susceptibility to inducers and inhibitors of CYP 3A4).</italic></p></annotation><pub-id pub-id-type="pmid">36649550</pub-id>
</mixed-citation>
          </ref>
          <ref id="Daridorexant.REF.pan.2023.587">
            <mixed-citation publication-type="journal"><string-name name-style="western"><surname>Pan</surname>
<given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Ge</surname>
<given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Lai</surname>
<given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Hou</surname>
<given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Tian</surname>
<given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname>
<given-names>Q</given-names></string-name>, <string-name name-style="western"><surname>Yang</surname>
<given-names>K</given-names></string-name>, <etal>et al.</etal>
<article-title>The comparative effectiveness and safety of insomnia drugs: a systematic review and network meta-analysis of 153 randomized trials.</article-title>
<source>Drugs.</source>
<year>2023</year>;<volume>83</volume>:<fpage>587</fpage>-<lpage>619</lpage>.<annotation><p><italic toggle="yes">(Systematic review of the literature on the safety of drugs for insomnia identified 61 trials with 25,093 patients, and while the frequency of common adverse events varied, &#x0201c;with respect to serious and drug related adverse events, there were no differences among the drugs&#x02019;; no mention of liver related adverse events).</italic></p></annotation><pub-id pub-id-type="pmid">36947394</pub-id>
</mixed-citation>
          </ref>
          <ref id="Daridorexant.REF.wang.2024.552">
            <mixed-citation publication-type="journal"><string-name name-style="western"><surname>Wang</surname>
<given-names>Q</given-names></string-name>, <string-name name-style="western"><surname>Zhou</surname>
<given-names>Q</given-names></string-name>, <string-name name-style="western"><surname>Du</surname>
<given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Lu</surname>
<given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Jiang</surname>
<given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Zhu</surname>
<given-names>H</given-names></string-name>. <article-title>Clinical safety of daridorexant in insomnia treatment: Analysis of FDA adverse event reports.</article-title>
<source>J Affect Disord.</source>
<year>2024</year>;<volume>362</volume>:<fpage>552</fpage>-<lpage>559</lpage>.<annotation><p><italic toggle="yes">(Among 1854 spontaneous reports to the FDA&#x02019;s Adverse Event Reporting System between 2022 and 2023 implicating daridorexant, most were for general disorders, psychiatric and neurologic events, only 3 were &#x0201c;hepatobiliary&#x0201d;; no details provided).</italic></p></annotation><pub-id pub-id-type="pmid">39019232</pub-id>
</mixed-citation>
          </ref>
        </ref-list>
      </sec>
      <sec sec-type="link-group" id="Daridorexant.OTHER_REFERENCE_LINKS">
        <title>OTHER REFERENCE LINKS</title>
        <p>1. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&#x00026;db=pubmed&#x00026;pubmedfilters=true&#x00026;term=(Daridorexant/AE)+AND+Human%5BMH%5D+AND+(drug+induced+liver+injury+OR+jaundice/CI+OR+bile+duct+diseases/CI+OR+liver/DE+OR+liver+diseases/CI)+AND+(%221900/1/1%22%5BEDat%5D:%222999/12/31%22%5BEDat%5D)">Recent References on Daridorexant: from PubMed.gov</ext-link></p>
        <p>2. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/results?term=Daridorexant">Trials on Daridorexant: from ClinicalTrials.gov</ext-link></p>
      </sec>
    </body>
  </book-part>
</book-part-wrapper>
